CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation
Here, we identify that immunosuppressive eADO signaling in the TME is a major barrier to oHSV therapy and CD73 blockade prevents tumor immune escape. The combination of oHSV with CD73 blockade supports the development of an antitumor immune memory response in solid tumors. This study supports clinical development of this combination strategy.
Authors
- Sara A. Murphy (ORCID: https://orcid.org/0000-0003-2722-0081)
- Cole T. Lewis (ORCID: https://orcid.org/0000-0002-2072-4677)
- Yan Cui (ORCID: https://orcid.org/0000-0002-2800-6039)
- Jiaqi Li (ORCID: https://orcid.org/0000-0001-9038-9010)
- Benedict Anchang
- Balveen Kaur
- E. Antonio Chiocca
- Upasana Sahu
- Jessica Swanner
Institutions
- Brigham and Women's Hospital (US)
- Augusta University (US)
- Augusta University Health (US)
- National Institute of Environmental Health Sciences (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- Louisiana State University Health Sciences Center New Orleans (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1136/jitc-2025-013640
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Alliance for Cancer Gene Therapy
- Amgen
- Cancer Prevention and Research Institute of Texas
- Dan L. Duncan Cancer Center, Baylor College of Medicine
- Augusta University
- University of Texas Health Science Center at Houston
- National Institutes of Health
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke
- National Institute of Dental and Craniofacial Research